Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Metrics to compare | PRME | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRMEPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −1.7x | −0.5x | |
PEG Ratio | −0.09 | −0.02 | 0.00 | |
Price/Book | 8.2x | 1.0x | 2.6x | |
Price / LTM Sales | 100.7x | 44.4x | 3.3x | |
Upside (Analyst Target) | 57.5% | 272.2% | 40.3% | |
Fair Value Upside | Unlock | 16.8% | 4.7% | Unlock |